Novartis: submits additional drug application for Kymriah.
(CercleFinance.com) - Novartis has said that it has submitted a supplemental biologics license application to the US FDA for Kymriah for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
If approved, this would be the second indication for Kymriah, that has already been approved for patients of up to 25 years old with B-cell precursor acute lymphoblastic leukemia.
A novel immunocellular therapy known as "CAR-T," Kymriah uses a patient's own T cells to fight cancer.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
If approved, this would be the second indication for Kymriah, that has already been approved for patients of up to 25 years old with B-cell precursor acute lymphoblastic leukemia.
A novel immunocellular therapy known as "CAR-T," Kymriah uses a patient's own T cells to fight cancer.
Copyright (c) 2017 CercleFinance.com. All rights reserved.